<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446419</url>
  </required_header>
  <id_info>
    <org_study_id>CIP 0003</org_study_id>
    <nct_id>NCT01446419</nct_id>
  </id_info>
  <brief_title>SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain</brief_title>
  <acronym>SMART</acronym>
  <official_title>A Prospective Randomized, Double-blind, Controlled Investigation Evaluating the Intracept Intraosseous Nerve Ablation System for the Reduction of Pain in Patients With Chronic Axial Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Relievant Medsystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Relievant Medsystems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of RF ablation using the Intracept Intraosseous Nerve&#xD;
      Ablation System to ablate intraosseous nerves for the relief of chronic axial low back pain.&#xD;
      This is a prospective, double-blind, randomized, sham-controlled clinical trial with an&#xD;
      optional crossover component.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ODI From Baseline to 3 Months Post-treatment</measure>
    <time_frame>3 months</time_frame>
    <description>The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain.&#xD;
ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Success at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of subjects with clinical success at 3 months, where clinical success was defined as:&#xD;
3 month ODI score represented at least a 15-point reduction from baseline&#xD;
no device or procedure related SAE between baseline and 3 mos.&#xD;
no increase in opioid use between procedure and 3 mos.&#xD;
no deficit in a motor or dermatomal sensory group at the treated level at 3 mos.&#xD;
no operative interventions or invasive procedures for lumbar back pain by a pain management or spinal specialist between procedure and 3 mos.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ODI From Baseline to 6 Months Post-treatment</measure>
    <time_frame>6 months</time_frame>
    <description>The improvement in ODI at 6 months compared to baseline.&#xD;
ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Intracept Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intracept Treatment</intervention_name>
    <description>Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.</description>
    <arm_group_label>Intracept Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.</description>
    <arm_group_label>Sham Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Skeletally mature patients age 25 - 70 years, inclusive&#xD;
&#xD;
          -  Chronic lower back pain for at least six (6) months&#xD;
&#xD;
          -  Failure to respond to at least six (6) months of non-operative conservative&#xD;
             management. The minimum requirement is as follows:&#xD;
&#xD;
               -  Analgesic therapy (minimum of 2 weeks) and a minimum of 4 weeks of NSAID therapy&#xD;
&#xD;
               -  Supervised exercise program(minimum of 12 sessions)&#xD;
&#xD;
          -  Oswestry Disability Index (ODI) at time of evaluation of at least 30 points&#xD;
&#xD;
          -  Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale&#xD;
&#xD;
          -  The following test indicating that the vertebral body is the source of pain:&#xD;
&#xD;
             1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one&#xD;
             or more levels from L3 to S1&#xD;
&#xD;
          -  Understands the local language and is willing and able to follow the requirements of&#xD;
             the protocol&#xD;
&#xD;
          -  Understands the informed consent and signs the institutional review board/ independent&#xD;
             ethics committee (IRB/IEC) approved informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radicular pain by history or evidence of pain or neurological deficit in a dermatomal&#xD;
             zone at or below the medial thigh.&#xD;
&#xD;
          -  Previous surgery performed on the lumbar spine&#xD;
&#xD;
          -  History of symptomatic spinal stenosis&#xD;
&#xD;
          -  History of osteoporotic or tumor-related vertebral body compression fracture&#xD;
&#xD;
          -  History of vertebral cancer or spinal metastasis&#xD;
&#xD;
          -  History of spinal infection&#xD;
&#xD;
          -  Metabolic bone disease (e.g. osteogenesis imperfecta)&#xD;
&#xD;
          -  BMI â‰¥40&#xD;
&#xD;
          -  Osteoporosis, defined as T score &lt;-2.5&#xD;
&#xD;
          -  Any radiographic evidence of other important back pathology, such as:&#xD;
&#xD;
               1. Nerve root compression or severe effacement of the thecal sac that correlates&#xD;
                  with radicular pain or muscle weakness&#xD;
&#xD;
               2. Disc extrusion or disc protrusion &gt;5mm&#xD;
&#xD;
               3. Facet arthrosis or facet effusion at any lumbar level that correlates with&#xD;
                  clinical evidence of facet mediated low back pain&#xD;
&#xD;
               4. Spondylolisthesis 2mm or greater at any level&#xD;
&#xD;
               5. Spondylolysis at any level&#xD;
&#xD;
          -  MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies.&#xD;
&#xD;
          -  Any back pathology related to trauma, evidence of vertebral compression fracture or&#xD;
             other spinal pathology that could affect assessment of response to back pain&#xD;
&#xD;
          -  Demonstrates 3 or more Waddell's signs of Inorganic Behavior&#xD;
&#xD;
          -  Any evidence of current systemic infection&#xD;
&#xD;
          -  Uncorrected bleeding diathesis&#xD;
&#xD;
          -  Any neurologic problem that prevents early mobilization after surgery or interferes&#xD;
             with assessment of ODI&#xD;
&#xD;
          -  Contraindication to MRI or patients who have allergies to the components of the&#xD;
             Intracept device&#xD;
&#xD;
          -  Pregnant, lactating or plan to become pregnant in next year&#xD;
&#xD;
          -  Diabetes requiring daily insulin&#xD;
&#xD;
          -  Current use of steroid therapy, with the exception of inhalation steroids for asthma&#xD;
&#xD;
          -  Evidence of mental instability or uncontrolled depression; patients requiring&#xD;
             anti-depressants or anti-psychotics within 3 months of enrollment are not eligible;&#xD;
             patients with a Beck Depression Score of greater than 24 are not eligible&#xD;
&#xD;
          -  Receiving Workmen's Compensation&#xD;
&#xD;
          -  Currently involved in litigation regarding back pain/injury or financial incentive to&#xD;
             remain impaired&#xD;
&#xD;
          -  Any medical condition that impairs follow-up&#xD;
&#xD;
          -  Contraindications to the proposed anesthetic protocol.&#xD;
&#xD;
          -  Evidence of substance abuse; patients using prescribed extended release narcotics are&#xD;
             not eligible (e.g. fentanyl patch,MS contin, oxycontin)&#xD;
&#xD;
          -  Known to require at the time of screening and/or randomization, additional surgery to&#xD;
             the lumbar spinal region within six months&#xD;
&#xD;
          -  Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid&#xD;
             therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)&#xD;
&#xD;
          -  Has a life expectancy of less than 1 year&#xD;
&#xD;
          -  Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators,&#xD;
             etc.&#xD;
&#xD;
          -  Is a prisoner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Fischgrund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Orthopaedic Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Desert Institute for Spine Care</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SpineCare Medical Group</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Orthopedic Surgical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Spine Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Center Solutions</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partners</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners in Research and Educational Studies of Spinal Disorders (PressD)</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroSpine Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Spine &amp; Scoliosis Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia iSpine Physicians</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <results_first_submitted>July 12, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2016</results_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic axial low back pain</keyword>
  <keyword>vertebrogenic pain</keyword>
  <keyword>Radio frequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 15 sites in the US and 3 sites in Germany</recruitment_details>
      <pre_assignment_details>2:1 Randomization (treatment: sham)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intracept Treatment</title>
          <description>Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back.</description>
        </group>
        <group group_id="P2">
          <title>Sham Treatment</title>
          <description>Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated per protocol</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat Population</population>
      <group_list>
        <group group_id="B1">
          <title>Intracept Treatment</title>
          <description>Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back.</description>
        </group>
        <group group_id="B2">
          <title>Sham Treatment</title>
          <description>Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="10.46"/>
                    <measurement group_id="B2" value="47.1" spread="8.97"/>
                    <measurement group_id="B3" value="47.0" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oswestry Disability Index (ODI)</title>
          <description>ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="10.73"/>
                    <measurement group_id="B2" value="41.1" spread="10.39"/>
                    <measurement group_id="B3" value="42.2" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in ODI From Baseline to 3 Months Post-treatment</title>
        <description>The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain.&#xD;
ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.</description>
        <time_frame>3 months</time_frame>
        <population>Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intracept Treatment</title>
            <description>Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ODI From Baseline to 3 Months Post-treatment</title>
          <description>The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain.&#xD;
ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.</description>
          <population>Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" lower_limit="-23.2" upper_limit="-17.8"/>
                    <measurement group_id="O2" value="-15.2" lower_limit="-18.7" upper_limit="-11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value from ANCOVA with factors of tx group, analysis center and tx group by analysis center interaction, and a covariate of baseline ODI score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Success at 3 Months</title>
        <description>Proportion of subjects with clinical success at 3 months, where clinical success was defined as:&#xD;
3 month ODI score represented at least a 15-point reduction from baseline&#xD;
no device or procedure related SAE between baseline and 3 mos.&#xD;
no increase in opioid use between procedure and 3 mos.&#xD;
no deficit in a motor or dermatomal sensory group at the treated level at 3 mos.&#xD;
no operative interventions or invasive procedures for lumbar back pain by a pain management or spinal specialist between procedure and 3 mos.</description>
        <time_frame>3 months</time_frame>
        <population>Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intracept Treatment</title>
            <description>Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Success at 3 Months</title>
          <description>Proportion of subjects with clinical success at 3 months, where clinical success was defined as:&#xD;
3 month ODI score represented at least a 15-point reduction from baseline&#xD;
no device or procedure related SAE between baseline and 3 mos.&#xD;
no increase in opioid use between procedure and 3 mos.&#xD;
no deficit in a motor or dermatomal sensory group at the treated level at 3 mos.&#xD;
no operative interventions or invasive procedures for lumbar back pain by a pain management or spinal specialist between procedure and 3 mos.</description>
          <population>Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5"/>
                    <measurement group_id="O2" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ODI From Baseline to 6 Months Post-treatment</title>
        <description>The improvement in ODI at 6 months compared to baseline.&#xD;
ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.</description>
        <time_frame>6 months</time_frame>
        <population>Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intracept Treatment</title>
            <description>Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back.</description>
          </group>
          <group group_id="O2">
            <title>Sham Treatment</title>
            <description>Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ODI From Baseline to 6 Months Post-treatment</title>
          <description>The improvement in ODI at 6 months compared to baseline.&#xD;
ODI is a patient questionnaire that assesses back dysfunction due to back pain. There are 10 questions that are scored from 0-5. The obtained score is multiplied by 2 to produce a percentage score that is reported on a scale of 0-100. Scores are interpreted as follows: 0-20% minimum disability; 21-40% moderate disability; 41-60% severe disability; 61-80% crippled; 81-100% bed bound or exaggerating their symptoms.</description>
          <population>Per Protocol Population: subjects that received the intended therapy per randomization assignment (appropriate ablation of the basivertebral nerve in the Intracept System arm) and completed follow-up per the study protocol.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" lower_limit="-23.4" upper_limit="-18.2"/>
                    <measurement group_id="O2" value="-17.0" lower_limit="-20.3" upper_limit="-13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Months</time_frame>
      <desc>Adverse Events reported for all Intent to Treat subjects from randomization through 12 months of follow-up</desc>
      <group_list>
        <group group_id="E1">
          <title>Intracept Treatment</title>
          <description>Intracept Treatment: Percutaneous access and RF ablation of the basivertebral nerve within the lumbar vertebral body to treat chronic axial low back.</description>
        </group>
        <group group_id="E2">
          <title>Sham Treatment</title>
          <description>Sham Treatment: Percutaneous access to the lumbar vertebra, no RF ablation delivered.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bacterial infection</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Airway obstruction on anaesthetic induction</sub_title>
                <description>Procedure related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Complications from lymph node excision</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis aggravated</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal seizure</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>CVA</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>C-section</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hip replacement</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bladder operation</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>Not related to device or procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site discomfort</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Post procedural nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="147"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Individual PIs will not publish any study results until completion of study and publication of the multi-center results in a peer-reviewed journal, which shall occur within one year after study completion. Thereafter, PIs may publish individual site experience. Sponsor can review results communications prior to public release and can embargo communications regarding results for a period that is less than or equal to 60 days from the time submitted to sponsor for review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>V.P. of Clinical &amp; Regulatory Affairs</name_or_title>
      <organization>Relievant Medsystems, Inc.</organization>
      <phone>650-261-2259</phone>
      <email>lhook@relievant.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

